

Rodolfo Cancado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8745837/publications.pdf>

Version: 2024-02-01

19

papers

367

citations

933447

10

h-index

888059

17

g-index

20

all docs

20

docs citations

20

times ranked

520

citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | A doença falciforme no Brasil. Revista Brasileira De Hematologia E Hemoterapia, 2007, 29, . | 0.7 | 94 |
| 2 | Intravenous iron therapy. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 461-469. | 0.7 | 70 |
| 3 | Iron deficiency in blood donors. Sao Paulo Medical Journal, 2001, 119, 132-134. | 0.9 | 44 |
| 4 | Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. Hepatology International, 2018, 12, 83-86. | 4.2 | 41 |
| 5 | Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-year Phase 2 study. European Journal of Haematology, 2015, 95, 545-550. | 2.2 | 34 |
| 6 | Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 439-443. | 0.7 | 14 |
| 7 | Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematology, Transfusion and Cell Therapy, 2021, 43, 341-348. | 0.2 | 14 |
| 8 | Analysis of HFE gene mutations and HLA-A alleles in Brazilian patients with iron overload. Sao Paulo Medical Journal, 2006, 124, 55-60. | 0.9 | 11 |
| 9 | Two-Year Analysis of Efficacy and Safety of Deferasirox Treatment for Transfusional Iron Overload in Sickle Cell Anemia Patients. Acta Haematologica, 2012, 128, 113-118. | 1.4 | 11 |
| 10 | Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study. Hematology, 2018, 23, 676-682. | 1.5 | 11 |
| 11 | Maternal and perinatal outcomes in pregnant women with sickle cell disease: an update. Hematology, Transfusion and Cell Therapy, 2022, 44, 369-373. | 0.2 | 9 |
| 12 | Novel mutations in the bone morphogenetic protein 6 gene in patients with iron overload and non-homozygous genotype for the HFE p.Cys282Tyr mutation. Blood Cells, Molecules, and Diseases, 2020, 84, 102444. | 1.4 | 6 |
| 13 | Guidelines on neonatal screening and painful vaso-occlusive crisis in sickle cell disease: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 147-157. | 0.7 | 3 |
| 14 | Iron replacement options: oral and intravenous formulations. Transfusion Alternatives in Transfusion Medicine, 2012, 12, 103-114. | 0.2 | 1 |
| 15 | Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply. Hematology, Transfusion and Cell Therapy, 2020, 42, 100-101. | 0.2 | 1 |
| 16 | Comprehensive healthcare for individuals with sickle cell disease. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 92-93. | 0.7 | 1 |
| 17 | Guidelines on the treatment of anemia of chronic renal failure using recombinant human erythropoietin: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Brasileira de Hematologia e Hemoterapia – 2014. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 450-453. | 0.7 | 0 |
| 18 | Pyruvate kinase deficiency: novel mutations and a better understanding of the genotype-to-phenotype correlation in Brazilian patients. Hematology, Transfusion and Cell Therapy, 2018, 40, 1-2. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Iron deficiency anemia and its treatment. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 245-245. | 0.7 | 0 |